GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allarity Therapeutics Inc (NAS:ALLR) » Definitions » Total Equity

Allarity Therapeutics (Allarity Therapeutics) Total Equity : $-6.47 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Allarity Therapeutics Total Equity?

Allarity Therapeutics's total equity for the quarter that ended in Mar. 2024 was $-6.47 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Allarity Therapeutics Total Equity Historical Data

The historical data trend for Allarity Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allarity Therapeutics Total Equity Chart

Allarity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
20.90 24.44 18.78 1.89 -2.75

Allarity Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 -0.72 -3.38 -2.75 -6.47

Allarity Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Allarity Therapeutics's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=11.862-14.613
=-2.75

Allarity Therapeutics's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=11.969-18.44
=-6.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allarity Therapeutics Total Equity Related Terms

Thank you for viewing the detailed overview of Allarity Therapeutics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Allarity Therapeutics (Allarity Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allarity Therapeutics Inc (NAS:ALLR) » Definitions » Total Equity
Comparable Companies
PBLA NBSE GSTC SONN ENSC ATXI ATNF RVLPQ ADIL CWBR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
24 School Street, 2nd Floor, Boston, MA, USA
Website
https://www.allarity.com
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improve clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
Executives
Laura Benjamin director 168 GOODRICH ST., LUNENBURG MA 01462
Joseph Walter Vazzano director 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Gerald W. Mclaughlin director 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
David Roth director C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joan Yvonne Brown officer: Chief Financial Officer C/O GOLDEN PHOENIX MINERALS, INC., 1675 EAST PRATER WAY, #102, SPARKS NV 89434
Steve Carchedi director, officer: Chief Executive Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Steen Knudsen officer: Chief Scientific Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Jens Erik Knudsen officer: Chief Financial Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Soren Gade Jensen director 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Duncan Moore director C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Thomas Jensen officer: SVP, Information Technology 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
James G. Cullem officer: SVP, Chief Business Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Marie Foegh officer: Chief Medical Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Sass & Larsen Aps 10 percent owner VESTERGARDSVEJ 6, GREVE G7 DK-2670
Leon Sass 10 percent owner JERNBAEK ALLE 5, HELSINGE G7 DK-3200